DDInter1796 DDInter1376
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Thioridazine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Thioridazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Thioridazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Thioridazine {u} (Compound) binds {v} (Gene) CYP2D6
Thioridazine {u} (Compound) upregulates {v} (Gene) KDM5B
Thioridazine {u} (Compound) palliates {v} (Disease) schizophrenia
Thioridazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Thioridazine {u} (Compound) downregulates {v} (Gene) VAPB
Thioridazine {u} (Compound) causes {v} (Side Effect) Cholestasis
Thioridazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Thioridazine (Compound) resembles Prochlorperazine (Compound)
Thioridazine (Compound) resembles Ethopropazine (Compound)
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine
Thioridazine (Compound) binds CYP2D6 (Gene)
Thioridazine (Compound) upregulates KDM5B (Gene)
Thioridazine (Compound) palliates schizophrenia (Disease)
Thioridazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Thioridazine (Compound) downregulates VAPB (Gene)
Thioridazine (Compound) causes Cholestasis (Side Effect)
Thioridazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide